Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelitolimod - TriSalus Life Sciences

Next Previous
X
Search
Drug Profile

Nelitolimod - TriSalus Life Sciences

Alternative Names: ISS-ODN SD-101; SD-101; SD101-Dynavax

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dynavax Technologies
  • Developer Bristol-Myers Squibb; Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; TriSalus Life Sciences; University of California, Davis
  • Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II B-cell lymphoma; Cholangiocarcinoma; Follicular lymphoma; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma
  • Phase I Pancreatic cancer; Uveal melanoma
  • Preclinical Colorectal cancer
  • No development reported Haematological malignancies; Hepatitis C; Solid tumours

Most Recent Events

  • 03 Jun 2024 Preliminary efficacy data from the PERIO-02 trial in Hepatocellular carcinoma released by TriSalus Life Sciences
  • 31 May 2024 Efficacy and adverse events data from phase-Ib/II PERIO-02 trial in Liver cancer and Cholangiocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 01 Apr 2024 Pharmacokinetics, immunogenicity, efficacy and adverse events data from the phase-I PERIO-01 trial in Uveal melanoma released by TriSalus Life Sciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top